CD38
CD38 is a glycoprotein found on the surface of many immune cells, including T cells, B cells and natural killer cells. Additionally, CD38 has been shown to be a bifunctional enzyme expressing both ADP-ribosyl cyclase and cADPR hydrolase activities. The role of CD38 in immune cells ranges from modulating cell differentiation to effector functions during inflammation, where CD38 may regulate cell recruitment, cytokine release, and NAD availability. In line with a role in inflammation, CD38 appears to also play a critical role in inflammatory processes during autoimmunity. Because of CD38 expression is highly upregulated on human plasma cells and especially on multiple myeloma cells.Targeting of CD38 is one of the most important and promising treatment avenues to help patients suffering from multiple myeloma.
All Product Categories
-
CD38 Related Products (41)
Related Products (41)
-
Recombinant Proteins (16)
-
Antibodies (1)
-
Lumrotatug
0 ImagesCat. No.: HY-P990747CAS No.: 2760318-99-6Synonyms: CM-313
-
SAR-442257
0 ImagesCat. No.: HY-P991183Purity: ≥99.0%SAR-442257 is a trispecific T-cell engager and monoclonal antibody that binds to CD38, CD3 and CD28. SAR-442257 can target and bind to CD3 and CD28 on T cells, as well as CD38 expressed on tumor cells. SAR-442257 mediates T-cell activation, enhances T-cell activity, induces T-cell degranulation, and drives cytotoxicity against multiple myeloma cells. SAR-442257 functions via CD38 expression, and its in vitro activity correlates with CD38 expression on the surface of multiple myeloma cells. SAR-442257 can be used in studies related to multiple myeloma and relapsed/refractory multiple myeloma.
-
Sanritatug
0 ImagesSynonyms: SG-301
-
Ara-F-NAD+
0 ImagesCat. No.: HY-134358CAS No.: 133575-27-6Ara-F-NAD+ is an arabino analogue of NAD+. Ara-F-NAD+ is a potent, reversible and slow-binding CD38 NADase inhibitor.
-
FTL004
0 ImagesCat. No.: HY-P991914FTL004 is an anti-CD38 monoclonal antibody. FTL004 exhibits enhanced Proapoptotic activity and displays stronger ADCC against CD38+ malignant cells. FTL004 can be used for the research of multiple myeloma and non-Hodgkin lymphoma[1].
-
NOTA-MK0159
0 ImagesCat. No.: HY-182345NOTA-MK0159 is a NOTA (HY-134418) and MK0159 (HY-150508) conjugate. NOTA-MK0159 inhibits human and mouse CD38 with IC50 values of 72.58 and 7.55 nM. NOTA-MK0159 coupled with radioactive elements acts as a imaging agent with specific uptake in CD38-positive multiple myeloma cells, enabling noninvasive whole-body assessment of CD38 expression in multiple myeloma xenografts. NOTA-MK0159 can be used for the research of multiple myeloma.
-
CVN14
0 ImagesCat. No.: HY-181543CAS No.: 2925663-26-7
-
Noraramtide
0 ImagesCat. No.: HY-P10563CAS No.: 2580150-96-3Synonyms: BHV-1100Noraramtide (BHV-1100) is an antibody-recruiting molecule. Noraramtide binds to CD38 and recruits natural killer (NK) cells to mediate antibody-dependent cellular cytotoxicity. Noraramtide enhances the capacity of autologous cytokine-induced memory-like (CIML) NK cells to produce IFNγ and CD107a, thereby improving their cytotoxicity against multiple myeloma cells. Noraramtide can be used in the research of multiple myeloma.
-
SAR442085
0 ImagesCat. No.: HY-P992455SAR442085 is an Fc-engineered anti-CD38 monoclonal antibody with a Kd of 0.2 nM for human CD38. SAR442085 inhibits CD38, induces apoptosis, and triggers antibody-dependent cellular cytotoxicity and phagocytosis in CD38-expressing tumor cells. SAR442085 binds allelic variants of FcγRIIa and FcγRIIIa, enhances NK cell activation, degranulation and cytokine secretion, and exerts anti-tumor activity in human Fc receptor transgenic mice. SAR442085 can be used in the research of multiple myeloma.
-
6-Alkyne-F-araNAD
0 ImagesCat. No.: HY-171417CAS No.: 1119281-04-7
-
A-3190
0 ImagesCat. No.: HY-184206A-3190 is an orally active, blood-brain barrier permeable CD38 inhibitor, with an IC50 of 7.25 nM against human CD38 and 1.24 nM against mouse CD38. A-3190 is a derivative of A-8531 (HY-184021), and it forms covalent adducts with NAD+ in the presence of CD38. A-3190 acts as an inducer of NAD+ levels and an inhibitor of NAM and ADPR levels. A-3190 increases NAD+ levels in the skin, lung, liver and brain of rodents, while reducing NAM and ADPR levels in brain tissues. A-3190 can be used in research related to multiple sclerosis, Parkinson's disease and Alzheimer's disease.
-
CID-103
0 ImagesCat. No.: HY-P991913Synonyms: TSK011010
-
CD38-IN-4
0 ImagesCat. No.: HY-156789CAS No.: 524055-93-4CD38-IN-4 is a CD38 inhibitor. CD38-IN-4 inhibits CD38 hydrolase enzymatic activity through mixed inhibition kinetics, binding partially inside and partially outside the NAD+ catalytic pocket. CD38-IN-4 acts as a DNA-binding agent. CD38-IN-4 can be used for research on neuroblastoma.
-
CD38 inhibitor 1 (Standard)
0 ImagesCat. No.: HY-123999RCAS No.: 1700637-55-3
-
CD38-IN-5
0 ImagesCat. No.: HY-164628CAS No.: 314039-40-2CD38-IN-5 (compound 1) is a CD38 inhibitor that selectively inhibits CD38 hydrolase with an IC50 of 4.0 μM. CD38-IN-5 does not inhibits CD38 cyclase. CD38-IN-5 is highly effective at promoting NK cell-mediated tumor toxicity. CD38-IN-5 increases NADH+ and IFNγ levels in activated PBMCs. CD38-IN-5 can be used for the study of cancer.
-
CD38-IN-7
0 ImagesCat. No.: HY-184493CAS No.: 2597933-37-2CD38-IN-7 is a CD38 inhibitor with an IC50 of less than 0.01 μM against hCD38. CD38-IN-7 can be used for research on various cancers.
-
GBR-1342
0 ImagesCat. No.: HY-P991462
